Xencor (XNCR) vs Zenas BioPharma (ZBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Xencor (XNCR) has outperformed Zenas BioPharma (ZBIO) over the past year, gaining 97.6% versus a gain of 1.3%. Xencor is the larger company by market cap ($1.83 billion vs $1.78 billion), about 1.0 times the size, while Zenas BioPharma is growing revenue faster (+100.0% vs +13.7%). Xencor converts more of its revenue into profit, with a net margin of -73.2% versus -3777.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | XNCR | ZBIO |
|---|---|---|
| Share price | $24.63 | $27.26 |
| Market cap | $1.83B | $1.78B |
| 1-day change | +0.53% | +3.89% |
| YTD return | +60.03% | -27.73% |
| 1-year return | +97.58% | +1.31% |
| 5-year return | -36.31% | — |
| EPS (TTM) | $-2.16 | $-9.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $125.58M | $10.00M |
| Revenue growth (YoY) | +13.65% | +100.00% |
| Net income (latest FY) | $-91.92M | $-377.74M |
| Operating margin | -141.35% | -3830.57% |
| Net margin | -73.20% | -3777.37% |
| 52-week high | $30.61 | $44.60 |
| 52-week low | $10.38 | $13.50 |
| Distance from 52-week high | -19.54% | -38.88% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +27.57% | +75.64% |
| Average volume | 1.32M | 733.34K |
| Shares outstanding | 74.35M | 65.18M |
| Employees | 260 | 167 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XNCR has outperformed ZBIO by 96.3 percentage points over the past year.
- Xencor is more profitable, keeping -73.2 cents of every revenue dollar as net income versus -3777.4 cents for Zenas BioPharma.
- Zenas BioPharma grew revenue faster in its latest fiscal year (+100.00% vs +13.65%).
About Xencor
XNCR stock →Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees
About Zenas BioPharma
ZBIO stock →Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus.
Health Care · Biotechnology: Pharmaceutical Preparations · 167 employees
XNCR vs ZBIO FAQ
Which is bigger, Xencor or Zenas BioPharma?
Xencor (XNCR) is larger, with a market capitalization of $1.83B compared with $1.78B for Zenas BioPharma (ZBIO).
Which stock has performed better over the past year, XNCR or ZBIO?
XNCR returned +97.58% over the past 12 months, compared with +1.31% for ZBIO (price return, excluding dividends). Past performance does not predict future results.
Are Xencor and Zenas BioPharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.